Hepatic Arterial Infusion of Doxorubicin-Loaded Microsphere for Treatment of Hepatocellular Cancer: A Multi-Institutional Registry - 22/09/11
, Lisa Rustein, MD, FACS c, Daniel Pérez Enguix, MD d, Julio Palmero, MD e, Victor Carvalheiro, MD f, Jose Urbano, MD g, Alessandro Valdata, MD h, Ivan Kralj, MD i, Petar Bosnjakovic, MD j, Cliff Tatum, MD b
Correspondence address: Robert CG Martin II, MD, PhD, University of Louisville, Department of Surgery, Division of Surgical Oncology, 315 E Broadway - #312, Louisville, KY 40202Résumé |
Background |
Hepatic intra-arterial therapy for unresectable hepatocellular cancer (HCC) has been shown to improve overall survival, but can have significant toxicity. A recent prospective randomized controlled trial demonstrated superior response rates and significantly less morbidity and doxorubicin-related adverse events with drug-eluting beads with doxorubicin (DEBDOX) compared with conventional chemoembolization. The aim of this study was to confirm the efficacy of DEBDOX for the treatment of unresectable HCC.
Study Design |
This open-label, multicenter, multinational single-arm study included 118 intermediate-staged HCC patients who were not candidates for transplantation or resection. Patients received DEBDOX at each treatment. Complications and response rates to treatment were analyzed.
Results |
There were 118 patients who received a total of 186 DEBDOX treatments with a median total treatment dose of 75 mg (range 38 to 150 mg), and median overall total hepatic exposure of 150 mg (range 150 to 600 mg). Five lesions were targeted, with a median size of 5.3 cm (range 1.0 to 16.9 cm). Severe adverse events related to liver dysfunction were seen after 4% of treatments. Overall survival was a median of 14.2 months (range 5 to 30 months), with progression-free survival of 13 months and hepatic-specific progression-free survival of 16 months. Okuda class less than 1 at time of treatment, reduction of alpha-fetoprotein of 1,000 ng/mL at the first post-treatment evaluation, delivery of more than 200 mg doxorubicin, and less than 25% liver involvement were all predictors of favorable overall survival assessed by multivariable analyses.
Conclusions |
Hepatic intra-arterial injection of DEBDOX is safe and effective in the treatment of HCC, as demonstrated by a minimal complication rate and robust and durable tumor response.
Le texte complet de cet article est disponible en PDF.Abbreviations and Acronyms : AFP, DEBDOX, HCC, HR, RECIST, TACE, TAE
Plan
| Disclosure Information: Dr Martin receives honoraria as a speaker for Biocompatibles. All other authors have nothing to disclose. |
Vol 213 - N° 4
P. 493-500 - octobre 2011 Retour au numéro
Article précédent
- Concomitant Endoscopic Radiofrequency Ablation and Laparoscopic Reflux Operative Results in More Effective and Efficient Treatment of Barrett Esophagus
- Trudie A. Goers, Pedro Leão, Maria A. Cassera, Christy M. Dunst, Lee L. Swanström
- Laparoscopic Liver Resection: An Examination of Our First 300 Patients
- Robert M. Cannon, Guy N. Brock, Michael R. Marvin, Joseph F. Buell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?